The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a comparable https://aliviaiute145885.humor-blog.com/37414954/retatrutide-vs-tirzepatide-a-comparative-analysis